GenSci reports on status of legal case

Jury trial expected later this year



Apr 12, 2001, 01:00 ET from GenSci Regeneration Sciences Inc.

    IRVINE, CA and TORONTO, ON, April 12 /PRNewswire/ - GenSci
 OrthoBiologics, Inc. (GenSci), a subsidiary of GenSci Regeneration Sciences
 Inc. (TSE: GNS), announced that a federal district court in Los Angeles has
 issued its rulings on summary judgment requests from both parties in the
 patent infringement suit between the Company and Osteotech, Inc.
     One of the summary judgment motions before the Court, which dealt with
 literal infringement, was granted to Osteotech. This pre-trial ruling does not
 mean that a judgment of actual infringement has been or will be entered. The
 Court has denied all other summary judgment requests pending from both GenSci
 and Osteotech. GenSci has filed an appellate writ to overturn the Court's
 decision and is still aggressively continuing to pursue several defensive
 strategies. GenSci expects to present these defenses, including the potential
 invalidation of Osteotech's patents, to a jury trial later this year.
     "Our goal in this legal dispute, as stated since early last year, is to
 prove that we do not infringe and to squarely put Osteotech's patents at risk
 by focusing our legal efforts on attacking the validity of its patents," said
 James M. DeMesa, M.D., President and Chief Executive Officer. "We remain
 confident in a positive outcome in this case."
     GenSci Regeneration Sciences Inc., The OrthoBiologics Company(TM), is
 focused on developing novel approaches to bone repair and regeneration,
 encouraging fewer minimally invasive procedures, thereby reducing the need for
 autograft surgical procedures and improving recuperation and rehabilitation,
 while reducing patient morbidity and infection rates, and post-op
 complications. GenSci designs, develops, manufactures, and markets
 biotechnology products in the areas of orthopedics, neurosurgery, and oral
 maxillofacial surgery.
 
     Certain statements contained herein are forward-looking within the
 meaning of the Private Securities Litigation Reform Act of 1995. These
 statements include the future outcomes of litigation. Such forward-looking
 statements involve known and unknown risks, uncertainties, and other factors,
 which may cause the actual results, performance or achievements of the company
 to be materially different from those expressed or implied. Forward-looking
 statements involve risks and uncertainties, including, but not limited to,
 such risks as are described in the company's annual report.
 
 

SOURCE GenSci Regeneration Sciences Inc.
    IRVINE, CA and TORONTO, ON, April 12 /PRNewswire/ - GenSci
 OrthoBiologics, Inc. (GenSci), a subsidiary of GenSci Regeneration Sciences
 Inc. (TSE: GNS), announced that a federal district court in Los Angeles has
 issued its rulings on summary judgment requests from both parties in the
 patent infringement suit between the Company and Osteotech, Inc.
     One of the summary judgment motions before the Court, which dealt with
 literal infringement, was granted to Osteotech. This pre-trial ruling does not
 mean that a judgment of actual infringement has been or will be entered. The
 Court has denied all other summary judgment requests pending from both GenSci
 and Osteotech. GenSci has filed an appellate writ to overturn the Court's
 decision and is still aggressively continuing to pursue several defensive
 strategies. GenSci expects to present these defenses, including the potential
 invalidation of Osteotech's patents, to a jury trial later this year.
     "Our goal in this legal dispute, as stated since early last year, is to
 prove that we do not infringe and to squarely put Osteotech's patents at risk
 by focusing our legal efforts on attacking the validity of its patents," said
 James M. DeMesa, M.D., President and Chief Executive Officer. "We remain
 confident in a positive outcome in this case."
     GenSci Regeneration Sciences Inc., The OrthoBiologics Company(TM), is
 focused on developing novel approaches to bone repair and regeneration,
 encouraging fewer minimally invasive procedures, thereby reducing the need for
 autograft surgical procedures and improving recuperation and rehabilitation,
 while reducing patient morbidity and infection rates, and post-op
 complications. GenSci designs, develops, manufactures, and markets
 biotechnology products in the areas of orthopedics, neurosurgery, and oral
 maxillofacial surgery.
 
     Certain statements contained herein are forward-looking within the
 meaning of the Private Securities Litigation Reform Act of 1995. These
 statements include the future outcomes of litigation. Such forward-looking
 statements involve known and unknown risks, uncertainties, and other factors,
 which may cause the actual results, performance or achievements of the company
 to be materially different from those expressed or implied. Forward-looking
 statements involve risks and uncertainties, including, but not limited to,
 such risks as are described in the company's annual report.
 
 SOURCE GenSci Regeneration Sciences Inc.